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Variants in transcription factor p63 have been linked to several autosomal dominantly inherited malformation syndromes. These
disorders show overlapping phenotypic characteristics with various combinations of the following features: ectodermal dysplasia,
split-hand/foot malformation/syndactyly, lacrimal duct obstruction, hypoplastic breasts and/or nipples, ankyloblepharon filiforme
adnatum, hypospadias and cleft lip/palate. We describe a family with six individuals presenting with a striking novel phenotype
characterized by a furrowed or cleft tongue, a narrow face, reddish hair, freckles and various foot deformities. Whole-exome
sequencing (WES) identified a novel heterozygous variant, c.3G>T, in TP63 affecting the translation initiation codon (p.1Met?).
Sanger sequencing confirmed dominant inheritance of this unique variant in all six affected family members. In summary, our
findings indicate that heterozygous variants in TP63 affecting the first translation initiation codon result in a novel phenotype
dominated by a cleft tongue, expanding the complex genotypic and phenotypic spectrum of TP63-associated disorders.
European Journal of Human Genetics; https://doi.org/10.1038/s41431-021-00967-x
INTRODUCTION
Heterozygous variants in transcription factor p63 encoded by TP63
[MIM 603273] have been linked to several autosomal dominantly
inherited malformation syndromes including ankyloblepharon-
ectodermal defects-cleft lip/palate syndrome (AEC [MIM 106260]),
acro-dermo-ungual-lacrimal-tooth syndrome (ADULT [MIM
103285]), ectrodactyly, ectodermal dysplasia, cleft lip/palate
syndrome 3 (EEC3 [MIM 604292]), limb-mammary syndrome
(LMS [MIM 603543]), split-hand/foot malformation type 4 (SHFM4
[MIM 605289]) and isolated orofacial cleft 8 (OFC8 [MIM 618149])
[1]. TP63-related disorders have overlapping phenotypic charac-
teristics with various combinations of the following features:
ectodermal dysplasia (subjective hypohidrosis, nail dysplasia,
sparse hair, skin erosions especially on the scalp associated with
areas of scarring and alopecia, hypopigmentation, trismus,
excessive freckling, tooth abnormalities), split-hand/foot malfor-
mation/syndactyly, lacrimal duct obstruction, hypoplastic breasts
and/or nipples, ankyloblepharon filiforme adnatum, hypospadias
and cleft lip/palate [1, 2].
TP63 is located on 3q28 and comprises 16 different exons [3, 4].
It is a member of the large p53 family of transcription factors and a
key regulator in epidermal development and differentiation [5].
Additionally, p63 has been linked to divers biological processes,
e.g., differentiation, proliferation, adhesion, stem cell maintenance,
apoptosis and aging [6, 7]. The wide spectrum of cellular functions
might be explained by the large number of p63 isoforms
identified yet. Two different transcription start sites lead to two
main classes of transcripts: TAp63 and ΔNp63. TAp63 contains
three TA-specific exons, exon 1, 2 and 3, and encodes a
transactivation domain (Fig. 1). The shorter isoform variant,
ΔNp63, uses an independent promotor in exon 3’ resulting in a
truncated transactivating domain [6, 8, 9]. In addition, alternative
splicing at the 3ʹ end of both the TAp63 and ΔNp63 transcripts
generates at least three different C-terminal variants (α, β, and γ)
[8, 10]. The longest 3′ splice variant (including the exons 11–14) is
the α isoform, which comprises a sterile alpha-motif (SAM)
involved in protein–protein interactions and a transactivation
inhibitory domain (TID) [10–13]. Two further variants, β (which
lacks exon 13) and γ (that does not contain the exons 11–14 but
has a γ-specific exon 10′), do not comprise the SAM and TID
domains [14, 15]. All isoforms contain the DNA-binding domain
and oligomerization domain (OD) [5, 8, 10, 16]. A wide spectrum of
different heterozygous germline variants in TP63 have been
identified as causative of the syndromes and malformations stated
above. According to the literature (HGMD Database Professional
2020.4), most of the reported disease-causing variants (110 of 153)
are missense variants. Variants associated with particular disorders
usually cluster in specific functional domains, indicating a
genotype-phenotype association [2, 4, 17]. For instance, variants
causing the EEC3 syndrome are generally located in the DNA-
binding domain, whereas variants leading to the AEC phenotype
are regularly found either in the SAM and transactivation
inhibitory domains or in the transactivating domain of the
ΔNp63 isoforms (Fig. 1) [2, 5, 18, 19]. These findings suggest that
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Fig. 1 Overview of the identified translation initiation codon variant in TP63 on genomic and protein level. A Chromatograms of the
identified TP63 variant in six affected family members (I.2, II.1, II.3, III.1, III.3 and III.4: c.3G>T; p.Met1?). B Schematic diagram of the human TP63
gene structure. Alternative promoter use produces TA (transactivation) and N-terminally truncated (ΔN) isoforms, and alternative splicing
produces C-terminal variants (α, β, γ). Colors within exons correspond to the different functional domains. Red arrow indicates the TP63 variant
identified within this study. Orange arrow indicates the most likely alternatively used start codon at position 40, resulting in a shortened
version of the TAp63 isoforms. Different TP63-associated disorders (ankyloblepharon-ectodermal defects-cleft lip/palate syndrome (AEC); acro-
dermo-ungual-lacrimal-tooth syndrome (ADULT); ectrodactyly, ectodermal dysplasia, cleft lip/palate syndrome 3 (EEC3); limb-mammary
syndrome (LMS); split-hand/foot malformation type 4 (SHFM4)) and the typical location of their variant are indicated by black brackets. C
Comparison of the six major isoforms encoded by TP63. Isoforms in the red box are potentially affected by the TP63 variant p.Met1?. Colors
correspond to the different functional domains.
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there might be specific molecular mechanisms for each TP63-
related condition.
Here, we describe a unique translation initiation codon variant
in TP63 identified in a family with a striking novel phenotype. The
variant, c.3G>T, affects the first transcription start site of p63 and is
predicted to lead to impaired function of the TAp63 isoforms. All
six patients carrying this variant show a cleft tongue.
CLINICAL REPORT
We describe six patients with cleft tongue (HP:0000221) who were
referred to our Institute of Human Genetics for clinical and
diagnostic evaluation. The cleft tongue (HP:0000221) was already
present at birth and did not change over time. Their sense of taste
was not affected and no signs of submucous cleft palate
were observed. The patients reported no difficulty in swallowing.
Fig. 2 Pedigree and clinical characteristics of individuals carrying the heterozygous c.3G>A variant in TP63. A Family pedigree, unfilled
shapes denote healthy individuals, filled shapes indicate those family members who are clinically affected. B Clinical characteristics of patient
II.1, II.3, III.1, III.3 and III.4. Facial features included a long narrow face (HP:0000275), hypotrophic jaw muscles (HP:0045037), reddish hair
(HP:0002297), freckels (HP:0001480) and a midline furrow of the tongue (HP:0000221).
J. Schmidt et al.
4
European Journal of Human Genetics
The clinical characteristics of the patients described in the present
report are summarized in Table 1. The family pedigree is illustrated
in Fig. 2A and is consistent with autosomal dominant inheritance.
The corresponding images are shown in Fig. 2B. The main clinical
features are summarized and compared to the typical clinical
findings of other TP63-associated disorders in Table 2.
Patient 1
The boy (III.1 in Fig. 2A) was born spontaneously after 39 weeks of
gestation. Birth weight was 3350 g (−0.3 SD), length 53 cm (−0.5
SD) and occipitofrontal head circumference (OFC) 35 cm (−0.2 SD).
Apgar scores were 10 at 5 and 10min, respectively. Due to
bilateral talipes equinovarus (HP:0001762) he required a series of
castings followed by night splinting. His psychomotor develop-
ment was slightly delayed. He walked independently at the age of
15 months and started to speak first words at the age of 2 years.
At clinical evaluation at 12 years and 4 months, height was 167 cm
(1.6 SD), weight 65.9 kg (1.8 SD), and OFC was 55.2 cm (0.4 SD). He
showed reddish hair (HP:0002297), freckles (HP:0001480), and a
narrow face (HP:0000275). His tongue showed a deep single
median furrow looking like a cleft tongue (HP:0000221). Serum
creatine kinase levels were unremarkable.
Patient 2
III.3 in Fig. 2A was born at term. His birth weight was 3630 g
(median), length 56 cm (1.5 SD) and OFC 36 cm (0.3 SD). Apgar
scores were 10 at 5 and 10min. Pigeon toes (HP:0001760) were
noted shortly after delivery. His development was slightly delayed.
He walked independently at the age of 16 months and started to
speak first words at the age of 20 months. He received speech-
and physiotherapy. At the age of 2 years and 4 months, he was
diagnosed with Langerhans’ cell histiocytosis, which could be
treated successfully with radiation. At 10 years and 6 months, his
height was 145 cm (0.2 SD), weight 37.9 kg (0.3 SD), and OFC was
55 cm (0.9 SD). He showed the following facial features:
narrow face (HP:0000275), reddish hair (HP:0002297), freckles
(HP:0001480), and a median furrowed tongue/cleft tongue
(HP:0000221). Serum creatine kinase levels were unremarkable.
Patient 3
The mother of patients III.1 and III.3 (II.1) showed similar facial
features as her affected sons including a narrow face
(HP:0000275), reddish hair (HP:0002297), freckles (HP:0001480)
and a median furrowed tongue/cleft tongue (HP:0000221). She
reported a mild muscular hypotonia (HP:0001252) of her legs. Her
height was 171.5 cm (0.5 SD), and OFC was 56 cm (−0.5 SD).
Patient 4
Patient I.2 showed also a median furrowed tongue/cleft tongue
(HP:0000221). She had a pointed foot as a child and reported
muscular hypotonia (HP:0001252). She reported that her already
deceased mother had similar symptoms, too.
Patient 5
The girl (III.4 in Fig. 2A) was born after 38 weeks of gestation by
Caesarean section. Her birth weight was 3500 g (0.8 SD), length
was 52 cm (0.75 SD) and OFC 34 cm (−0.2 SD). Apgar scores were
10 at 5 and 10min, respectively. She received physiotherapy due
to muscular hypotonia (HP:0001252) and uses orthopedic insoles
due to flat valgus foot. Otherwise, her psychomotor development
was normal. She walked independently at the age of 15 months
and started to speak first words at the age of 1 year. At clinical
evaluation at 12 years and 4 months, her height was 167.2 cm (1.6
SD), weight 65.9 kg (1.8 SD), and OFC was 55.2 cm (0.4 SD). She
showed the following characteristic facial features: narrow face
(HP:0000275), reddish hair (HP:0002297), freckles (HP:0001480),
and a median furrowed tongue/cleft tongue (HP:0000221).
Patient 6
Patient II.3 showed a narrow and hypotonic facies (HP:0000275),
reddish hair (HP:0002297), and a median deeply grooved tongue
(HP:0000221). Bilateral talipes equinovarus (HP:0001762) were
noted shortly after birth. She had surgical extension of the Achilles
tendon at the age of three months and required a series of
castings. Congenital hip dysplasia (HP:0001385) was treated with
Pavlik Harness. Her motor development was delayed. She walked
independently at the age of 2 years and 6 months. She reported
Table 2. Summary of the clinical findings in our patients with the main clinical feature of cleft tongue (CT) (HP:0000221) compared to the typical
clinical findings of different TP63-associated disorders: ankyloblepharon-ectodermal defects-cleft lip/palate syndrome (AEC); acro-dermo-ungual-
lacrimal-tooth syndrome (ADULT); ectrodactyly, ectodermal dysplasia, cleft lip/palate syndrome 3 (EEC3); limb-mammary syndrome (LMS); split-hand/
foot malformation type 4 (SHFM4) and isolated orofacial cleft 8 (OFC8) [1]. Human Phenotype Ontology (HPO) [40].
Feature TP63-related disorder
HPO CT AEC ADULT EEC3 LMS SHFM4 OFC8
Ankyloblepharon filiforme adnatum HP:0009755 +
Ectodermal dysplasia: HP:0000968 + + + rare
Hypohidrosis (mostly subjective) HP:0000966 + + +
Nail dysplasia HP:0002164 + + mild +
Sparse hair HP:0008070 + + +
Tooth abnormalities HP:0000164 + + + +
Cleft lip/palate HP:0000202 + + + +
Cleft/furrowed tongue HP:0000221 +
Split-hand/foot malformation/syndactyly HP:0002813 + + + + +
Lacrimal duct obstruction HP:0000579 + + + +
Dermal erosions HP:0200041 +
Hypopigmentation HP:0007513 + + +
Hypospadias HP:0000047 + +
Trismus HP:0000211 +
Freckling HP:0001480 + +
Hypoplastic breasts HP:0010311 +
Hypoplastic nipples HP:0006709 +
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muscular hypotonia (HP:0001252) of her legs. Her height was
165.8 cm (−0.4 SD) and OFC was 54.5 cm (−0.7 SD). Earlier genetic
testing for facioscapulohumeral muscular dystrophy (FSHD),
Emery–Dreifuss muscular dystrophy, Hauptmann–Thannhauser
muscular dystrophy and Charcot-Marie-Tooth disease was
unremarkable.
MOLECULAR STUDIES AND RESULTS
Written informed consent was obtained from all participants or
their legal representatives prior to the participation in the study,
and DNA from participating family members was extracted from
peripheral blood lymphocytes by standard extraction procedures.
The study was approved by the Ethics Committee of University
Medical Center Göttingen (approval number 3/2/16) and per-
formed in accordance with the Declaration of Helsinki protocols.
We performed whole-exome sequencing (WES) on DNA extracted
from blood of the patients III.1, III.2 and III.4, using the Agilent
SureSelectXT Human All Exon V7 enrichment kit on an Illumina
HiSeq4000 sequencer. The exome and genome analysis pipeline
“Varbank 2.0” (https://varbank.ccg.uni-koeln.de/varbank2) of the
Cologne Center for Genomics (CCG, University of Cologne,
Germany) was used to analyze the exome data using the
following filter criteria: coverage of more than 6 reads, a minimum
quality score of 10, and a minor allele frequency (MAF) < 1.0% in
the gnomAD (https://gnomad.broadinstitute.org) database. We
obtained a mean coverage of 92–99 and 95.7%–96.2% of targets
were covered more than 10×. The following databases were used
to obtain gene information: National Center for Biotechnology
Information (NCBI; https://www.ncbi.nlm.nih.gov), Ensembl Gen-
ome Server (http://www.ensembl.org), UCSC Genome Bioinfor-
matics (http://genome-euro.ucsc.edu) and Genome Aggregation
Database (gnomAD; http://gnomad.broadinstitute.org). We
focused on heterozygous variants present in all three affected
individuals consistent with a dominant transmission in line with
the family history. We identified a heterozygous variant in TP63
(RefSeq NM_003722.5) not present in any current database of
human genetic variations including the gnomAD (https://gnomad.
broadinstitute.org) database (last access date 10/02/2021, [20])
and predicted to have a severe impact on protein function. This
heterozygous missense variant, c.3G>T, was located in exon 1 of
the TP63 gene (Fig. 1) and affects the first transcription start site of
p63, leading to impaired TAp63 isoforms (p.Met1?). The variant
was predicted as disease-causing by MutationTaster (http://www.
mutationtaster.org), damaging by SIFT (https://sift.bii.a‐star.edu.
sg), probably damaging by PolyPhen‐2 (http://genetics.bwh.
harvard.edu/pph2), and has a CADD (https://cadd.gs.washington.
edu) score of 25.6, indicating deleteriousness of this variant.
According to NetStart 1.0 (score of 0.599; http://www.cbs.dtu.dk/
services/NetStart/), TIS Miner (score of 0.791; http://dnafsminer.bic.
nus.edu.sg/Tis.html), ATGpr (score of 0.48; https://atgpr.dbcls.jp/
cgi-bin/atgpr.cgi) and the ORF finder (https://www.ncbi.nlm.nih.
gov/orffinder/) the most likely alternatively used start codon is the
next downstream AUG codon at position 40, resulting in a
shortened version of the isoform originally annotated as TAp63
(Fig. 1B). Sanger sequencing was used to validate the WES data
and to prove that the other affected family members, II.1, II.3 and
I.2, do carry the heterozygous variant as well (Fig. 2A). No
additional patient material was available for detailed isoform
characterization.
DISCUSSION
In this study, we present a three-generation family with six
individuals showing a striking novel phenotype, characterized by a
furrowed or cleft tongue, a narrow face, reddish hair, freckles and
various foot deformities. Despite intensive research, we were not
able to identify a similar case in the literature and to make a
specific clinical diagnosis, so we decided to perform variant
analysis by whole-exome sequencing. We selected the three most
distantly related affected family members to reduce the amount
of shared benign variants and to maximize the segregation
filtering power. Focusing on heterozygous variants consistent with
a dominant transmission in line with the family history, we
identified a heterozygous variant, c.3G>T, in TP63 affecting the
translation initiation codon (p.1Met?). Heterozygous variants in
TP63 have been linked to several syndromic and isolated diseases
[5, 18] with partly overlapping phenotypes and various combina-
tions of the following features: ectodermal dysplasia (e.g., nail
dysplasia, sparse hair, hypopigmentation, freckling, tooth abnorm-
alities), split-hand/foot malformation/syndactyly, lacrimal duct
obstruction, hypoplastic breasts and/or nipples, ankyloblepharon
filiforme adnatum, hypospadias and cleft lip/palate [1, 2]. The
large number of p63 isoforms might explain the wide spectrum of
TP63-associated diseases (Fig. 1). Two different transcription start
sites lead to two main classes of transcripts: TAp63 and ΔNp63
[6, 8, 9]. Furthermore, alternative splicing at the 3ʹend of both the
TAp63 and ΔNp63 transcripts generates at least three different
C-terminal variants (α, β, and γ) [8, 10]. Cleft tongue has not been
linked as a characteristic feature to TP63-related disorders until
now [21–23]. However, other TP63 variants have been described to
cause forms of orofacial clefts including cleft lip, cleft palate and
cleft uvula [24–26]. Interestingly, especially loss-of-function
variants in TP63 seem to result in a phenotype dominated by
oral clefting [5]. So far, no TP63 variant has been described that
affects the translation initiation codon of the first transcription
start site, neither as disease-causing (HGMD Database Professional
2020.4) nor in healthy controls (https://gnomad.broadinstitute.org;
last access date 10/02/2021, [20]). The most likely used next start
codon is at position 40, leading to a shortened version of the
TAp63 isoforms. For further verification, we validated the WES data
and performed segregation analysis. The TP63 variant, c.3G>T, was
found in all six affected family members by Sanger sequencing,
supporting our theory that this unique variant causes a novel
TP63-associated phenotype.
The specific phenotype of the reported patients might indicate
that the affected TAp63 isoforms are especially expressed during a
specific period of the development during embryogenesis.
Tongue development is a complex process starting around week
4 of embryonic development [27]. The muscles of the tongue
predominantly derive from the myoblasts, which originate in the
occipital somites, and tongue connective tissue and vasculature
are derived from cranial neural crest cells [28, 29]. Reciprocal
interactions between cranial neural crest cells and myogenic cells
are essential in the coordination of tongue development, and
deep single median furrows on the dorsal surface of the tongue or
a cleft tongue can occur if this complex process is disturbed [30].
Expression analysis of different TP63 isoforms indicates that TAp63
is the dominant isoform expressed in skeletal muscle and plays a
critical role specifically in late myogenic differentiation stages [31],
providing an explanation for the observed phenotypic differences
between patients described in this study and previously described
TP63-associated phenotypes. Specifically, TAp63γ contributes to
muscle growth, remodeling and functional differentiation by
controlling specific sub-sets of target genes, and it is involved in
the formation of atrophic myotubes and reduced myoblasts fusion
index [32]. Dysfunction of TAp63, therefore, might directly affect
myoblast fusion during tongue development, resulting in a deep-
furrowed/cleft tongue, and, furthermore, provide an explanation
for the muscular hypotonia that is present in varying degrees in all
our patients. Further investigations are required to verify this
hypothesis.
In general, the occurrence of a cleft tongue with or without
other abnormalities is rare. Most of the other syndromes related
with cleft/furrowed or bifid tongue, such as orofaciodigital
syndrome 1 [MIM 311200], Robinow syndrome [MIM 180700] or
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distal arthrogryposis type 5D [MIM 615065], are as well associated
with other forms of orofacial clefts, e.g., cleft lip and/or cleft palate.
Among the genetic causes associated with these phenotypes,
pathogenic variants in DVL1/DVL3 and WNT5A (all (i.a.) for
Robinow syndrome) and TCTN3 (orofaciodigital syndrome 4) have
been identified. Encoded proteins are involved in different cellular
pathways which, like the sonic hedgehog (SHH) and WNT
pathways, are key signaling pathways during development and
maintenance of various tissues and, similar to p63, regulate
expression of a huge variety of target genes [33–35]. Interestingly,
it has been shown that p63 can modulate both pathways and act
as an activator of SHH signaling as well as a repressor of canonical
WNT signaling in different tissues and developmental stages
[36, 37]. However, these regulations can be exerted by different
isoforms of TP63, including ΔNp63 variants, which are not affected
by the variant identified in this study [38]. Therefore, it remains
highly speculative whether the observed phenotype is caused by
direct interaction of p63 with these pathways.
Additionally, we found by extensive research of the literature a
further hint in line with our assumption. Pries et al. reported in
1974 three patients with EEC syndrome showing a furrow in the
midline of the tongue [39], too. Consistent with the clinical
diagnosis of EEC syndrome, these patients showed further
malformations including ectodermal dysplasia as well as cleft lip
and palate. One of the patients with furrowed tongue reported by
Pries et al. had additional split-hand/foot malformation. Overall,
they were more severely affected than the patients described
here. The genetic cause of these cases is unfortunately unknown.
We can only speculate what kind of variant might have caused
their specific phenotype, but still, the phenotypic overlap to the
patients presented in this study is quite striking. Interestingly,
muscular hypotonia was not mentioned as a clinical feature in
these three cases. Actually, it remains unclear whether the
muscular hypotonia that is present in varying degrees in all of
our patients can be explained by the TP63 variant. Despite
intensive efforts, we were not able to identify any additional
genetic cause of this. Presenting these cases will contribute to
identify further families with hereditary cleft tongue due to
variants in TP63, which will help to gain further insights into p63-
associated pathomechanisms and to answer these open
questions.
In summary, our findings indicate that heterozygous variants in
TP63 affecting the first translation initiation codon result in a novel
phenotype dominated by a cleft tongue, expanding the complex
genotypic and phenotypic spectrum of TP63-associated disorders.
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